A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
|Articles|August 10, 2022
Daily OTC Pearl: Aftera
Author(s)Saro Arakelians, PharmD
Aftera is an emergency contraceptive that reduces the chance of pregnancy after unprotected sex.
Advertisement
OTC/Lifestyle Pearl of the Day: Aftera
Indication: Aftera is an emergency contraceptive thatreduces the chance of pregnancy after unprotected sex.
Insight:
- Contains: Colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, potato starch, talc.
- Levonorgestrel 1.5mg
- Take as soon as possible within 72 hours after unprotected sex. The sooner you take it, the better it will work. If you vomit within 2 hours after taking the medication, call a health care professional to find out whether you should repeat the dose.
- Keep out of reach of children.
Advertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5